GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MIL:1GILD) » Definitions » Valuation Rank

Gilead Sciences (MIL:1GILD) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Gilead Sciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MIL:1GILD) » Definitions » Valuation Rank
Comparable Companies
PFE BMY AMGN MRK BIIB OGN AMRN SCLX MDCX MIRA LLY JNJ ABBV OCSE:NOVO B XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4519
Traded in Other Exchanges
GILD:USA GILD:Mexico GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina
Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).